Celsee Diagnostics Adds Another Patent to IP Portfolio
Collaborative studies will determine the feasibility of using circulating tumor cells (CTCs) as a biospecimen for mutation analysis.
Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, and GENEWIZ, a global leader in R&D genomics services, announced today that they have entered into a collaboration to determine the feasibility of using circulating tumor cells (CTCs) as a biospecimen for mutation analysis.
During the studies, GENEWIZ will test the CTC enrichment technology of the Celsee PREP100 to determine the technical feasibility and performance using Sanger Sequencing and NGS-based assays to identify mutations in cancer cell lines and clinical blood specimens. The study will assess DNA viability from CTCs and measure cancer-specific DNA mutations/variants in the isolated CTCs. The development of the technology will facilitate cancer research in understanding of mechanisms of metastasis.
“Retrieval and genomic analysis of CTCs by using the Celsee PREP100 platform is of extreme interest to our customers. The most efficient way to demonstrate this capability is to partner with a leader in the space of genome research. GENEWIZ has all the right credentials – expertise, capability and global reach. We look forward to working with their team,” stated Celsee Diagnostics’ Chief Scientific Officer Yixin Wang, Ph.D.
“We are always searching for innovative ways to assist the scientific community to more quickly and accurately get the data they need to advance scientific research,” said GENEWIZ’s Vice President of Research & Development Conrad Leung, Ph.D. “This collaboration with Celsee propels us to the forefront of oncology research on CTCs, which will be a nice complement to our existing genomic services and solutions.”
About Celsee Diagnostics
Celsee Diagnostics, a privately-held Michigan-based company, develops automated systems for rare CTC enrichment and single-cell analysis. The company’s precise, accurate, and reliable platform for research and clinical diagnostics development will allow healthcare professionals more time to focus on their patients’ therapeutic treatment and outcomes. The label-free Celsee PREP platforms perform all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH and mRNA FISH, while the Celsee ANALYZER scans and analyzes the prepared slide automatically. For more information, visit www.celsee.com.
GENEWIZ is a global leader in R&D genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high throughput sequencing, bioinformatics, and GLP regulatory-compliant services.
Headquartered in South Plainfield, NJ, GENEWIZ has a global network of laboratories in Boston, Washington DC, Research Triangle Park, San Diego, Los Angeles, San Francisco, and Seattle. International locations include Beijing, Suzhou and Tianjin, China, United Kingdom, and Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, and Weibo.